1. Home
  2. STNE vs CRNX Comparison

STNE vs CRNX Comparison

Compare STNE & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo StoneCo Ltd.

STNE

StoneCo Ltd.

HOLD

Current Price

$10.84

Market Cap

3.3B

Sector

Technology

ML Signal

HOLD

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$38.40

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STNE
CRNX
Founded
2012
2008
Country
Cayman Islands
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3B
3.9B
IPO Year
2018
2018

Fundamental Metrics

Financial Performance
Metric
STNE
CRNX
Price
$10.84
$38.40
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
8
Target Price
$19.19
$76.75
AVG Volume (30 Days)
4.8M
928.8K
Earning Date
05-14-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,039,000.00
Revenue This Year
$15.07
$720.10
Revenue Next Year
$6.05
$184.67
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.58
$25.83
52 Week High
$19.95
$57.99

Technical Indicators

Market Signals
Indicator
STNE
CRNX
Relative Strength Index (RSI) 25.33 48.28
Support Level N/A $33.19
Resistance Level $15.80 $45.32
Average True Range (ATR) 0.64 1.46
MACD -0.40 -0.03
Stochastic Oscillator 0.70 27.17

Price Performance

Historical Comparison
STNE
CRNX

About STNE StoneCo Ltd.

StoneCo Ltd is a provider of financial technology solutions. It serves MSMBs solutions, at fair prices, and provides the customer experience to help them manage their businesses and sell more. Its Stone Business Model combines end-to-end, cloud-based technology platforms; differentiated hyper-local and integrated distribution approaches; and white-glove, on-demand customer service. It has two segments Financial Services segment, which includes payments solutions, digital banking, credit, insurance solutions as well as the registry business. In the Software segment solution includes POS/ERP, TEF and QR Code gateways, reconciliation, CRM, OMS, e-commerce platform, engagement tool, ads solution, and marketplace hub. It generates the majority of its revenue from the Financial Services segment.

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

Share on Social Networks: